Microfluidic Platform for Multiplexed Cell Sampling and Time-Resolved SPR-Based Cytokine Sensing

Novak, Richard M.; Wartmann, David; Mathies, Richard A.; Dostálek, Jakub; Ertl, Peter

doi:10.1007/978-3-319-11128-5_195

Cited by 5 publications

(5 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[31,126] They can also use other transducing elements. TNF-𝛼 FI 20 pg mL −1 10 5 -10 6 pg mL −1 -Near real time [227] IFN-𝛾 FI 1.5 × 10 4 pg mL −1 (0.2-8) × 10 5 pg mL −1 -≈6 h [130] IFN-𝛾 FI 2 pg mL −1 5-10 2 pg mL −1 -≈30 min [33] IFN-𝛾 FI 0.1 pg mL −1 0.1-1.5 × 10 3 pg mL −1 -≈2 h [131] IFN-𝛾 FI 2 pg mL −1 0-10 2 pg mL −1 -≈45 min [228] IFN-𝛾, TNF-𝛼 FI 21 pg mL −1 0-3.6 × 10 2 pg mL −1 -≈40 min [128] IL-1𝛽 FI 3.2 pg mL −1 3.5-2 × 10 2 pg mL −1 5-10 µL - [35] IL-20 FI 0.2 pg mL −1 2-2 × 10 4 pg mL −1 5 µL - [229] IL-1𝛽 FI 4.7 pg mL −1 13-2 × 10 2 pg mL −1 1 µL - [230] IL-1𝛽 FI 10 pg mL −1 25-4 × 10 2 pg mL −1 -- [125] IL-6 FI 1 pg mL −1 1-4 × 10 2 pg mL −1 1 µL - [37] IL-6 FI 0.1 pg mL −1 0.4-4 × 10 2 pg mL −1 1 µL - [231] IFN-𝛾 FI 10 3 pg mL −1 5 × 10 3 -1 × 10 5 pg mL −1 -Near real time [32] IL-2, IL-4, IL-6 SPR 5-20 pg mL −1 10-10 4 pg mL −1 1 µL ≈40 min [24] IL-6 SPR 10 pg mL −1 10-10 2 pg mL −1 -≈30 min [232] IL-6, TNF-𝛼 SPR 5 pg mL −1 4-5 × 10 2 pg mL −1 -- [137] IL-6, IL-4, IL-10,TNF-𝛼 SPR 20 pg mL −1 10-10 4 pg mL −1 1 µL ≈30 min [233] IFN-𝛾 SPR 5 × 10 4 pg mL −1 (0.5-8) × 10 5 pg mL −1 800 µL Real time [136] IL-6 SPR 10 4 pg mL −1 10 4 -2 × 10 5 pg mL −1 100 µL Real time [138] TGF-𝛽1 E C 1 0 p g m L −1 15-3 × 10 3 pg mL −1 25 µL ≈60 min [234] IL-6, IL-1𝛽, TNF-𝛼 EC 5 pg mL −1 5-2 × 10 2 pg mL −1 -- [28] IFN-𝛾 EC 1.6 pg mL −1 2.5-2 × 10 3 pg mL −1 5 µL ≈200 s [152] IFN-𝛾 EC 0.2 ng mL −1 0.2-2.8 × 10 2 ng mL −1 -- [156] IFN-𝛾 EC 3 pg mL −1 10-5 × 10 3 pg mL −1 30 µL ≈60 min [155] TNF-𝛼 EC -1-15 pg mL −1 -- [235] IFN-𝛾 EC 6 pg mL −1 10-5 × 10 2 pg mL −1 100 µL Real time [31] VEGF EC 0.1 pg mL −1 2-5 × 10 2 pg mL −1 -Real time [126] TNF-𝛼 EC 0.1 pg mL −1 0.1-1.5 × 10 2 pg mL −1 -≈20 min [29] IL-1𝛽, IL-10 EC 0.3 pg mL −1 (IL-10) 0.7 pg mL −1 (IL-1𝛽)…”

Section: Biosensors For Cytokines Detectionmentioning

confidence: 99%

Cytokines: From Clinical Significance to Quantification

et al. 2021

View full text Add to dashboard Cite

Cytokines are critical mediators that oversee and regulate immune and inflammatory responses via complex networks and serve as biomarkers for many diseases. Quantification of cytokines has significant value in both clinical medicine and biology as the levels provide insights into physiological and pathological processes and can be used to aid diagnosis and treatment. Cytokines and their clinical significance are introduced from the perspective of their pro‐ and anti‐inflammatory effects. Factors affecting cytokines quantification in biological fluids, native levels in different body fluids, sample processing and storage conditions, sensitivity to freeze‐thaw, and soluble cytokine receptors are discussed. In addition, recent advances in in vitro and in vivo assays, biosensors based on different signal outputs and intracellular to extracellular protein expression are summarized. Various quantification platforms for high‐sensitivity and reliable measurement of cytokines in different scenarios are discussed, and commercially available cytokine assays are compared. A discussion of challenges in the development and advancement of technologies for cytokine quantification that aim to achieve real‐time multiplex cytokine analysis for point‐of‐care situations applicable for both biomedical research and clinical practice are discussed.

show abstract

Section: Biosensors For Cytokines Detectionmentioning

confidence: 99%

Cytokines: From Clinical Significance to Quantification

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Isolation, expansion, modification and reimplantation of patient-derived blood cells is considered a promising strategy for future immune cell therapies for personalized medicine. , In a final set of experiments, automated cell capture, immunostaining and in situ analysis were accomplished using integrated micropumps to enable the “sample in and result out” function. Only on-chip integration of micropumps allows for automated on-chip sample treatment including rinsing, labeling and washing routinesall of which are prerequisites for high throughput screening applications. − Our automated phenotyping platform was capable of discriminating between low expressing and high expressing surface receptors within subpopulations of primary blood cells, since only high surface marker expressing cells are able to interact with the nanobiointerface under flow conditions. Results of our phenotyping study showed that cells exhibiting high receptor expression levels and strong binding affinity to the rSbpA/ZZ nanobiointerface, such as cytotoxic T cells, are preferentially retained during our microfluidic cell capture protocol.…”

Section: Discussionmentioning

confidence: 99%

Development of a Multifunctional Nanobiointerface Based on Self-Assembled Fusion-Protein rSbpA/ZZ for Blood Cell Enrichment and Phenotyping

Rothbauer

Frauenlob

Gutkas

et al. 2017

ACS Appl. Mater. Interfaces

Self Cite

View full text Add to dashboard Cite

We present a multifunctional nanobiointerface for blood cell capture and phenotyping applications that features both excellent antifouling properties and high antibody activity. Multifunctionality is accomplished by modifying polymeric materials using self-assembled S-layer fusion-protein rSbpA/ZZ to immobilize high density antibodies at the two protein A binding sites of the rSbpA/ZZ nanolattice structure. Controlled orientation and alignment of the antibodies reduced antibody consumption 100-fold and increased cell capture efficiency 4-fold over standard methodologies. Cell analysis in complex samples was made possible by the remarkable antifouling properties of the rSbpA domain, while at the same time reducing unspecific binding and forgoing tedious blocking procedures. An automated microfluidic in situ cell analysis platform for isolation and phenotyping of primary peripheral blood mononuclear cells was developed as practical application. Results obtained using our automated microfluidic cell analysis platform showed that the multifunctional nanobiointerface can discriminate among T helper and cytotoxic T cells, and thymocytes. Additionally, on-chip cell capture under flow conditions using a high affinity CD 3 selective nanobiointerface preferentially isolated cells with strong surface marker expression. This means that our dynamic microfluidic cell purification method allows the enrichment of 773 CD 8 positive cytotoxic T cells out of a total blood cell population of 7728 PBMCs, which is an increase in cell enrichment of 8-fold with a purity of 85%.

show abstract

“…Routinely used immunofluorescence end-point analysis can now be extended with complementary, continuous monitoring techniques (Charwat et al, 2013a(Charwat et al, ,b, 2014Picher et al, 2013;Novak et al, 2015). Several portable and miniaturized sensors have been developed over the past years to analyze rapidly changing biological systems.…”

Section: Integrated Sensing Functions For Microfluidic Cell Analysis mentioning

confidence: 99%

Automated, Miniaturized, and Integrated Quality Control-on-Chip (QC-on-a-Chip) for Cell-Based Cancer Therapy Applications

et al. 2015

Self Cite

View full text Add to dashboard Cite

The combination of microfabrication-based technologies with cell biology has laid the foundation for the development of advanced in vitro diagnostic systems capable of evaluating cell cultures under defined, reproducible, and standardizable measurement conditions. In the present review, we describe recent lab-on-a-chip developments for cell analysis and how these methodologies could improve standard quality control in the field of manufacturing cell-based vaccines for clinical purposes. We highlight in particular the regulatory requirements for advanced cell therapy applications using as an example dendritic cell-based cancer vaccines to describe the tangible advantages of microfluidic devices that overcome most of the challenges associated with automation, miniaturization, and integration of cell-based assays. As its main advantage, lab-on-a-chip (LoC) technology allows for precise regulation of culturing conditions, while simultaneously monitoring cell relevant parameters using embedded sensory systems. State-of-the-art lab-on-a-chip platforms for in vitro assessment of cell cultures and their potential future applications for cell-based strategies for cancer immunotherapy are discussed in the present review.

show abstract

Microfluidic Platform for Multiplexed Cell Sampling and Time-Resolved SPR-Based Cytokine Sensing

Cited by 5 publications

References 4 publications

Cytokines: From Clinical Significance to Quantification

Cytokines: From Clinical Significance to Quantification

Development of a Multifunctional Nanobiointerface Based on Self-Assembled Fusion-Protein rSbpA/ZZ for Blood Cell Enrichment and Phenotyping

Automated, Miniaturized, and Integrated Quality Control-on-Chip (QC-on-a-Chip) for Cell-Based Cancer Therapy Applications

Contact Info

Product

Resources

About